Silence Therapeutics plc (SLN)
Oxford Ledge is still expanding full research coverage of SLN. A live quote, fundamentals, and analysis are available in the app; the SEC-sourced material below is what we currently have indexed here.
Business summary
Silence Therapeutics develops RNA interference-based therapeutics through research collaborations and partnerships.
SEC filings
- 8-K Regulation FD disclosure; Financial statements and exhibits 2026-06-23
- 8-K Shareholder vote results 2026-06-16
- 8-K Other material event; Financial statements and exhibits 2026-06-11
- 8-K Entry into material agreement; Termination of material agreement; Other material event; Financial statements and exhibits 2026-05-18
- 10-Q Quarterly financial report (unaudited) 2026-05-07
Source: SEC EDGAR.
Insider activity
5 recent insider (SEC Form 4) filings on record for SLN. View the transactions in the terminal.
Source: SEC EDGAR (Form 4).
- Open SLN in the Oxford Ledge terminal — live quote, chart, and analysis in the app.
- Browse the covered-stock index
- Learn to analyze stocks yourself
The material above is drawn from public SEC EDGAR filings and is provided for educational purposes, not as investment advice. Live pricing and fundamentals are available in the terminal.